Galectin Therapeutics Inc. (NASDAQ:GALT – Free Report) – Research analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for Galectin Therapeutics in a note issued to investors on Tuesday, June 17th. HC Wainwright analyst M. Keller anticipates that the company will post earnings of ($0.16) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.67) EPS, FY2026 earnings at ($0.65) EPS and FY2027 earnings at ($0.72) EPS.
Galectin Therapeutics Stock Up 37.7%
Shares of NASDAQ GALT opened at $3.29 on Thursday. The firm’s 50-day moving average price is $1.43 and its 200-day moving average price is $1.44. Galectin Therapeutics has a 52-week low of $0.73 and a 52-week high of $3.30. The company has a market cap of $208.22 million, a PE ratio of -4.57 and a beta of 0.54.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geneos Wealth Management Inc. boosted its holdings in Galectin Therapeutics by 8.8% in the first quarter. Geneos Wealth Management Inc. now owns 423,235 shares of the company’s stock worth $516,000 after purchasing an additional 34,300 shares during the last quarter. HighTower Advisors LLC boosted its stake in shares of Galectin Therapeutics by 244.1% in the 1st quarter. HighTower Advisors LLC now owns 77,375 shares of the company’s stock worth $94,000 after buying an additional 54,889 shares during the last quarter. Nuveen LLC purchased a new position in shares of Galectin Therapeutics in the 1st quarter worth $34,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Galectin Therapeutics in the first quarter worth $287,000. Finally, Sovran Advisors LLC increased its position in Galectin Therapeutics by 7.4% during the first quarter. Sovran Advisors LLC now owns 199,830 shares of the company’s stock valued at $244,000 after acquiring an additional 13,816 shares during the last quarter. Institutional investors own 11.68% of the company’s stock.
About Galectin Therapeutics
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Featured Articles
- Five stocks we like better than Galectin Therapeutics
- What Makes a Stock a Good Dividend Stock?
- Robinhood Director Sells Millions, But HOOD Stock Eyes Gains
- How to Read Stock Charts for Beginners
- Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill
- What Do S&P 500 Stocks Tell Investors About the Market?
- Super Micro Computer Stock’s Rally Backed by Strong Financials
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.